AXSM AXS-12: May 2027 Cataplexy PDUFA, Two Phase 3 Wins

The FDA accepted Axsome Therapeutics’ NDA for AXS-12 (reboxetine) for cataplexy in narcolepsy on July 15, 2026, with a PDUFA date of May 1, 2027. No advisory committee is planned.

Axsome (NASDAQ: AXSM) closed at $238.37, a ~$12.3 billion market cap on 51.5 million shares. The stock has run on Auvelity (depression) and Sunosi (narcolepsy); AXS-12 extends the sleep medicine franchise.

What the data showed

The NDA rests on two Phase 3 trials, SYMPHONY (NCT05059223) and ENCORE (NCT05113745). In ENCORE, 68 patients randomized to continue AXS-12 or switch to placebo saw weekly cataplexy attacks rise 10.29 on placebo versus 1.32 on drug (p=0.017). In SYMPHONY, AXS-12 cut weekly attacks 83% versus 66% on placebo (rate ratio 0.49, p=0.018), with 33% of patients in complete remission versus 9.5% on placebo.

AXS-12 also improved daytime sleepiness and cognitive function. No serious adverse events were reported in SYMPHONY; common side effects were dry mouth, nausea, and constipation, all mild to moderate. ENCORE reported no new safety signals with long-term dosing.

How the drug works

AXS-12 is a highly selective norepinephrine reuptake inhibitor and cortical dopamine modulator. It modulates noradrenergic activity to maintain muscle tone during wakefulness; dopaminergic signaling promotes wakefulness and cognition. Reboxetine was marketed as an antidepressant in Europe but never approved in the US; Axsome is developing it for narcolepsy.

Why this matters

Cataplexy, sudden loss of muscle tone triggered by emotion, affects roughly 70% of narcolepsy type 1 patients. Current options carry real limitations. Sodium oxybate (Jazz’s Xyrem and Xywav) is effective but carries a heavy sodium load and strict REMS distribution. Pitolisant (Harmony’s Wakix) is approved for daytime sleepiness and cataplexy but works through histamine modulation. Antidepressants are used off-label.

If approved, AXS-12 would be the first therapy specifically approved for cataplexy. The selective NRI mechanism offers a different approach for patients who cannot tolerate sodium oxybate or need additional control.

Competitive context

The narcolepsy field is getting crowded. Takeda’s oveporexton, a first-in-class orexin receptor agonist, showed greater than 80% cataplexy reduction in Phase 3 and targets the underlying orexin deficiency that drives narcolepsy type 1. That drug has a PDUFA in Q3 2026 and could reach the market well before AXS-12. Axsome’s advantage is an established commercial infrastructure through Sunosi, though oveporexton’s mechanism-based approach may prove more durable.

What to watch

The May 1, 2027 PDUFA is 278 days out. No advisory committee is a positive signal. The key risk is the competitive window: if Takeda’s oveporexton launches in late 2026, it could reshape physician expectations before AXS-12 reaches market. Watch for FDA information requests in early 2027.

Further background on the regulatory timeline is in our guide to PDUFA dates. The Phase 3 SYMPHONY topline results were published in Neurology, and trial details are on ClinicalTrials.gov.